Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02193113
Recruitment Status : Completed
First Posted : July 17, 2014
Last Update Posted : March 3, 2017
Sponsor:
Collaborator:
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
KalVista Pharmaceuticals, Ltd.

Brief Summary:
This is a Phase 1 study to investigate the safety, tolerability of the novel plasma kallikrein inhibitor, KVD001 in subjects with diabetic macular edema. The study is the first step to investigate the hypothesis that plasma kallikrein plays an important role in the disease process behind diabetic macular edema in many patients

Condition or disease Intervention/treatment Phase
Diabetic Macular Edema Drug: KVD001 Injection Phase 1

Detailed Description:

The plasma kallikrein-kinin system has long been recognized as a key player in inflammatory processes, capillary leakage and angiogenesis in various organs. Recent work suggests that plasma kallikrein is central to the pathogenesis of Diabetic Macular Edema (DME) and that activation of the enzyme contributes to the excessive retinal vascular permeability leading to DME. Among different persons with DME, plasma kallikrein contributes both independently in some, and in association with Vascular Endothelial Growth Factor (VEGF) in others. However, the effect of plasma kallikrein appears to be independent of VEGF. Thus, growing scientific evidence points to plasma kallikrein inhibitors as an exciting potential new therapeutic opportunity directed at a novel VEGF-independent pathway that may reduce retinal vascular permeability and treat DME, in patients whose disease process is, at least in part, driven by the plasma kallikrein pathway.

This is an open label, single ascending dose study to investigate the safety, tolerability and pharmacodynamics of a novel plasma kallikrein inhibitor administered by intravitreal (IVT) injection in subjects with central involved diabetic macular edema and reduced vision.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision
Actual Study Start Date : July 18, 2014
Actual Primary Completion Date : June 4, 2015
Actual Study Completion Date : June 4, 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema

Arm Intervention/treatment
Experimental: KVD001 Injection Dose 1
Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
Drug: KVD001 Injection
A novel plasma kallikrein inhibitor
Other Name: KVD001

Experimental: KVD001 Injection Dose 2
Single 100uL intravitreal injection KVD001 injection Dose 2
Drug: KVD001 Injection
A novel plasma kallikrein inhibitor
Other Name: KVD001

Experimental: KVD001 Injection Dose 3
Single 100uL intravitreal injection of KVD001 injection Dose 3
Drug: KVD001 Injection
A novel plasma kallikrein inhibitor
Other Name: KVD001




Primary Outcome Measures :
  1. Number of participants with Adverse Events as a measure of safety and tolerability [ Time Frame: 56 days ]

Secondary Outcome Measures :
  1. Measurement of KVD001 plasma levels over time following intravitreal injection (with calculation of Tmax, Cmax, AUC and t1/2) [ Time Frame: 28 days ]
  2. Best Corrected Visual Acuity as measured by ETDRS EVA [ Time Frame: 56 days ]

Other Outcome Measures:
  1. Change in retinal thickness from baseline [ Time Frame: 84 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female adult subjects 18 years of age and older
  2. Confirmed diagnosis of Type I or Type II diabetes mellitus
  3. Best corrected visual acuity, using Early Treatment Diabetic Retinopathy Study (ETDRS) electronic visual acuity (EVA) testing, of between 20/40 and 20/400 (Snellen equivalent) in the study eye
  4. Fellow eye acuity 20/80 or better measured as above with no expectation of requirement for anti-VEGF treatment in fellow eye within 2 months of study drug administration
  5. Presence of central involved DME in the study eye defined as Optical Coherence Tomography (OCT) Central Subfold Thickness (CST) ≥305 µm in women and ≥320 µm in men in the study eye
  6. Subjects who fulfil one of the following criteria:

    1. Subjects who have not previously received an anti-VEGF treatment and who, in the view of the Investigator, can have initiation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration
    2. Subjects who are receiving regular anti-VEGF intravitreal injections who:

      • Have received at least 3 intravitreal injections of an anti-VEGF treatment within the last 5 months (study drug administration will be at least 6 weeks after the most recent intravitreal administration of anti-VEGF) and
      • In the view of the Investigator, can have continuation of anti-VEGF treatment in the study eye deferred for at least 2 months following the date of anticipated study drug administration
    3. Subjects who have received anti-VEGF in the past (>3 months prior to study inclusion) but are not actively receiving treatment and who in the view of the Investigator, can have resumption of anti-VEGF or alternative treatment in the study eye deferred for at least 2 months following anticipated study drug administration
  7. Subjects, who in the view of the Investigator, are not expected to require panretinal laser photocoagulation or intravitreal steroids or intraocular surgery in the study eye for at least 2 months following anticipated study drug administration
  8. No prior treatment with panretinal photocoagulation or intravitreal steroid in the study eye within the previous 3 months
  9. No prior treatment with systemic corticosteroids or systemic anti-VEGF therapy within the previous 3 months
  10. Study participant voluntarily agrees to participate in this study and signs the Institutional Review Board (IRB) approved informed consent prior to performing any procedure

Exclusion Criteria:

  1. Females who are pregnant or lactating, or expecting to become pregnant during the course of the study
  2. Poorly controlled diabetes mellitus
  3. Uncontrolled hypertension
  4. Significant co-existing disease
  5. Participation in an investigational intervention clinical study within 2 months prior to study inclusion
  6. History of alcohol and/or drug abuse in the last 2 years
  7. Men not willing to use appropriate birth control methods
  8. Media clarity or pupillary dilation inadequate to obtain reasonable quality OCT and/or fundus image
  9. Subjects employed by the Sponsor or in any relationship of dependence with the Sponsor and/or Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02193113


Locations
Layout table for location information
United States, California
Retina Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
United States, Indiana
Raj K. Maturi, MD PC
Indianapolis, Indiana, United States, 46290
United States, Massachusetts
Beetham Eye Institute
Boston, Massachusetts, United States, 02215
United States, South Carolina
Palmetto Retina Center
West Columbia, South Carolina, United States, 29169
United States, Texas
Valley Retina Institute, PA
McAllen, Texas, United States, 78503
Sponsors and Collaborators
KalVista Pharmaceuticals, Ltd.
Juvenile Diabetes Research Foundation
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Sun, MD, MPH Joslin Diabetes Center
Principal Investigator: David Boyer, MD Retina-Vitreous Associates Medical Group
Principal Investigator: Victor Gonzalez, MD Valley Retina Institute, PA
Principal Investigator: Raj Maturi, MD Midwest Eye Institute
Principal Investigator: Jack Wells, MD Palmetto Retina Center
Additional Information:
Layout table for additonal information
Responsible Party: KalVista Pharmaceuticals, Ltd.
ClinicalTrials.gov Identifier: NCT02193113    
Other Study ID Numbers: KVD001-001
First Posted: July 17, 2014    Key Record Dates
Last Update Posted: March 3, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by KalVista Pharmaceuticals, Ltd.:
Diabetic Macular Edema
DME
Plasma Kallikrein inhibitor
KVD001
KVD001-001
Intravitreal
IVT
Diabetes mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Edema
Edema
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases